LSX World Congress USA, Boston, 11-12 September 2024.

The LSX World Congress USA gathers leaders from the US biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology.

(August 2024)

NLS Days, Malmö, Sweden, 18-19 September 2024.

Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business.

(August 2024)

LSX Nordic Congress, Copenhagen, Denmark, 8-9 October 2024.

The LSX Nordic Congress connects life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalisation of Nordic & Baltic life science and healthcare innovation.

The mission is to facilitate ever greater international investment into the region, as well as foster strategic partnerships and collaboration with key international healthcare stakeholders.

(August 2024)

Bio Europe, Stockholm, Sweden, 4-6 November 2024.

BIO-Europe is the gateway to the global biopharma community and celebrates 30 years of facilitating partnerships. The conference convenes over 5,500 attendees, representing 60 countries and 2,800+ companies, making the event the industry's largest gathering of biopharma professionals in Europe.

(August 2024)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

(October 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

(June 2018)